UNSPSC 51373311: Aspirin/caffeine/dihydrocodeine

This classification denotes a combination drug defined by the U.S. Department of Veterans Affairs in its (VA's) National Drug File (NDF), which falls under VA Drug Class CN101. This VA Drug Class (CN101) classifies this compound as belonging to the group OPIOID ANALGESICS.

UNSPSC 51373311 Aspirin/caffeine/dihydrocodeine is a Commodity code that, based on recent state and local solicitations, covers the procurement of generic pharmaceuticals and over-the-counter products by public health agencies, state health and human services commissions, and cooperative purchasing organizations. The code does not capture the abstract drug combination in its name alone—state and local buyers are acquiring these and related generics through large-scale supply agreements with manufacturers and authorized wholesalers, often bundling multiple therapeutic categories and OTC lines in single procurements. Issuing bodies include state health departments and human services commissions (Texas HHS Commission), county public health systems (Seminole County, Florida), and multi-state cooperative purchasing vehicles (Minnesota Multistate Cooperative Purchasing Alliance, which includes participating jurisdictions across Minnesota and Oregon). These entities typically require manufacturers to certify compliance with current Good Manufacturing Practices and the Drug Supply Chain Security Act, maintain relationships with authorized wholesalers, offer flexible pricing models, and provide comprehensive product documentation including National Drug Codes and expiration-date assurances.

Recent activity spans Texas, Florida, and Minnesota–Oregon cooperative territory. The Minnesota Multistate Cooperative Purchasing Alliance (MMCAP) issued an RFP on January 20, 2026, with a March 26, 2026, response deadline, seeking multiple-award contracts for generic pharmaceuticals and OTC products to be supplied through AmerisourceBergen, Cardinal Health, and Morris & Dickson, with contract effectiveness on July 1, 2026, and evaluation weighted 75 percent on price competitiveness. Seminole County, Florida released IFB 60459723LAS on June 30, 2026, with a July 26, 2023, response deadline, procuring 1,900 units of Naloxone and 800 Safe Drug Deactivation Systems annually through quarterly deliveries to the county's Community Health Building, with a two-year initial term and optional one-year renewal. The Texas Health and Human Services Commission posted RFI HHS0017013 in April 2026 to gather market intelligence on direct-to-manufacturer prescription fulfillment capabilities—an exploratory phase that signals the state's intent to shift procurement strategy away from traditional pharmacy benefit manager and group purchasing organization channels toward negotiated net-pricing models with manufacturers.